Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: LUNGevity Foundation, Caris Life Sciences, Deep Lens, Genetic Technologies

NEW YORK –  LUNGevity Foundation this week launched an online patient resource, called Lung Cancer Patient Gateways, that helps patients find treatment information, educational resources, and patient and caregiver support. The first resource LUNGevity is launching is the KRAS Patient Gateway to help patients learn about KRAS mutations, find specialists and clinical trials, and join KRAS-specific patient and caregiver communities. Over the next six months, LUNGevity will launch five other gateways including resources for different types of lung cancer, including non-small cell and small cell lung cancer, and tumors driven by mutations in genes such as ALK, EGFR, ROS1, MET, NTRK, BRAF, and RET.

Caris Life Sciences said this week that its Precision Oncology Alliance (POA) and the National Cancer Institute's Center for Cancer Research will collaborate on precision medicine research initiatives. As part of the collaboration, Caris will make its suite of comprehensive molecular profiling offerings available to NCI researchers and will link molecular testing results into an electronic medical records database to create a more complete dataset of combined patient outcomes and molecular information. According to Caris, joining the POA network will enable the NCI faculty and researchers to conduct clinical and translational research collaboratively across the alliance, participate in ongoing research activities across POA tumor groups, and generate and publish clinical outcomes data that impacts cancer care. The POA currently involves 55 cancer centers and academic institutions including 24 NCI-designated cancer centers.

Bioinformatics firm Deep Lens this week announced it has partnered with Southern Oncology Specialists to help expand patients' access to clinical trials using its Viper artificial intelligence platform. Southern Oncology Specialists, a comprehensive cancer practice that treats patients throughout the Carolinas, hopes to offer more clinical trials within its practice and match patients to trials at diagnosis using Deep Lens' platform. Deep Lens will use Viper to screen cancer patients for trials using clinical information in Southern Oncology Specialists' electronic medical records system and incorporate data from pathology and molecular tests performed by Caris Life Sciences, Guardant Health, Foundation Medicine, and Tempus. Deep Lens offers its screening and clinical trial matching solution to oncology practices at no cost.

In reporting its first quarter fiscal year 2022 financial results, Melbourne-based Genetic Technologies this week said it has submitted a validation package to the Australian National Association of Testing Authorities for its Genetype MultiTest assay, which gauges patients' risks for common cancers that account for approximately 70 percent of annual morbidities. The company plans to initially launch the test for determining risk of breast, colorectal, prostate, and ovarian cancers, as well as for coronary artery disease and type 2 diabetes.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.